ONKOLOGIE / Onkologie. 2024;18(3):193-200 / www.onkologiecs.cz 200 PŘEHLEDOVÉ ČLÁNKY Současné terapeutické strategie léčby očního melanomu GSK2141795 in patients with advanced uveal melanoma. Journal of Clinical Oncology. 2016;34(15_suppl):9511-9511. 49. Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(4):357-366. 50. Amaro AA, Gangemi R, Emionite L, et al. Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma. Cancers (Basel). 2023;15(3). 51. Wu X, Li J, Zhu M, et al. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther. 2012;11(9):1905-1914. 52. Park JJ, Stewart A, Irvine M, et al. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling. Cancer Gene Therapy. 2022;29(10):1384-1393. 53. Cao L, Chen S, Sun R, et al. Darovasertib, a novel treatment for metastatic uveal melanoma. Front Pharmacol. 2023;14:1232787. 54. Chen X, Wu Q, Tan L, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. 2014;33(39):4724-4734. 55. Bauer S, Larkin J, Hodi FS, et al. A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Frontiers in Oncology. 2023;12. 56. Khalili JS, Yu X, Wang J, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18(16):4345-4355. 57. Pereira PR, Odashiro AN, Marshall JC, et al. The role of c-kit and imatinib mesylate in uveal melanoma. J Carcinog. 2005;4:19. 58. Penel N, Delcambre C, Durando X, et al. O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs. 2008;26(6):561-565. 59. Sacco J, Nathan P, Danson S, et al. Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma. Journal of Clinical Oncology. 2013;31:9031-9031. 60. Mouriaux F, Servois V, Parienti JJ, et al. Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. Br J Cancer. 2016;115(1):20-24. 61. Bhatia S, Moon J, Margolin KA, et al. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One. 2012;7(11):e48787. 62. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011;2(12):1097-1105. 63. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol. 2006;124(10):1428-1434. 64. Yang H, Jager MJ, and Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci. 2010;51(6):2835-2842. 65. Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17(20):6574-6581. 66. Piperno-Neumann S, Diallo A, Etienne-Grimaldi MC, et al. Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. Oncologist. 2016;21(3):281-282. 67. Sharma A, Stei MM, Fröhlich H, et al. Genetic and epigenetic insights into uveal melanoma. Clin Genet. 2018;93(5): 952-961. 68. Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713. 69. Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18(2):408-416. 70. Dai W, Zhou J, Jin B, et al. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep. 2016;6:22622. 71. Jespersen H, Olofsson Bagge R, Ullenhag G, et al. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer. 2019;19(1):415. 72. Faião-Flores F, Emmons MF, Durante MA, et al. HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. Clin Cancer Res. 2019;25(18):5686-5701. 73. Booth L, Roberts JL, Sander C, et al. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα(q) and Gα(11) and kill uveal melanoma cells. Cancer Biol Ther 2019;20(5):700-710. 74. Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020;22(4):497-505. 75. Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol. 2009;35(11):1192-1197. 76. Mariani P, Almubarak MM, Kollen M, et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol. 2016;42(5):706-712. 77. Servois V, Bouhadiba T, Dureau S, et al. Iterative treatment with surgery and radiofrequency ablation of uveal melanoma liver metastasis: Retrospective analysis of a series of very long-term survivors. Eur J Surg Oncol. 2019;45(9):1717-1722. 78. Ghanaati H, Mohammadifard M, Mohammadifard M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. J Family Med Prim Care. 2021;10(10):3553-3560. 79. Sundram FX, Buscombe JR. Selective internal radiation therapy for liver tumours. Clin Med (Lond). 2017;17(5):449-453. 80. Laface C, Laforgia M, Molinari P, et al. Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers (Basel). 2021;13(12). 81. Dewald CLA, Warnke MM, Brüning R, et al. Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience. Cancers (Basel). 2021;14(1). 82. Bailey FP, Clarke K, Kalirai H, et al. Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. Pigment Cell Melanoma Res. 2018;31(2):253-266. 83. Croce M, Ferrini S, Pfeffer U, et al. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. Cancers (Basel). 2019;11(6). 84. Béliveau A, Bérubé M, Rousseau A, et al. Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma. Invest Ophthalmol Vis Sci. 2000;41(8):2363-2372. 85. Lai K, Conway RM, Crouch R, et al. Expression and distribution of MMPs and TIMPs in human uveal melanoma. Exp Eye Res. 2008;86(6):936-941. 86. Advani R, Flinn I, Popplewell L, et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma. N Engl J Med. 2018;379(18):1711-1721. 87. Li YF, Dong L, Li Y, Wei WB. A Review of MicroRNA in Uveal Melanoma. Onco Targets Ther. 2020;13:6351-6359. 88. Li Y, Luo JT, Liu YM, et al. miRNA-145/miRNA-205 inhibits proliferation and invasion of uveal melanoma cells by targeting NPR1/CDC42. Int J Ophthalmol. 2020;13(5):718-724. 89. Qi Y, Cui Q, Zhang W, et al. Long Non-Coding RNA GAS5 Targeting microRNA-21 to Suppress the Invasion and Epithelial-Mesenchymal Transition of Uveal Melanoma. Cancer Manag Res. 2020;12:12259-12267. 90. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010;16(24): 6083-6092. 91. Bilmin K, Synoradzki KJ, Czarnecka AM, et al. New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma. Cancers (Basel). 2021;14(1). 92. Kines RC, Varsavsky I, Choudhary S, et al. An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma. Mol Cancer Ther. 2018;17(2):565-574. www.onkologiecs.cz Onkologie
RkJQdWJsaXNoZXIy NDA4Mjc=